BioElectronics

05/28/2026

Contact us for more information: 301 874-4890 or [email protected]

https://www.instagram.com/reels/DYztFgQjMb1/

05/24/2026

Today, we pause to remember and honor the brave men and women who made the ultimate sacrifice for our country. We reflect with gratitude on the freedoms we enjoy because of those who gave everything to protect them.

From all of us at BioElectronics Corporation, we wish you and your family a safe, meaningful, and reflective Memorial Day.

04/22/2026

We’ve officially announced the expansion of ActiPatch® into Taiwan—bringing FDA-cleared, drug-free pain therapy to a new and growing international market.

This launch represents a key step in our growth strategy—partnering with high-quality distributors to deliver non-invasive, long-duration pain relief to patients who are actively seeking alternatives to drugs.

ActiPatch delivers:
✔️ Up to 720 hours of continuous therapy
✔️ Drug-free, non-invasive pain relief
✔️ No sensation, no disruption to daily life
✔️ Proven use across musculoskeletal conditions

As healthcare systems worldwide look to reduce reliance on opioids and NSAIDs, demand for safe, effective alternatives continues to grow.

👉 We are actively seeking distribution partners in additional markets

If you have reach in:
• Retail pharmacy
• Medical / DME distribution
• International markets
• Physical therapy, chiropractic, or surgical networks

We want to connect. This is a proven, FDA-cleared platform ready to scale. [email protected] or 301.874.4890

02/09/2026

The BioElectronics R&D team is seeking a physician or clinical researcher who is interested in collaborating on a vulvodynia-focused study to evaluate the effectiveness of RecoveryRx for treating vulvodynia pain.

RecoveryRx is a class II, USA FDA-cleared, drug-free, non-invasive, disposable, non-thermal shortwave therapy device that utilizes radio-frequency electromagnetic energy to modulate nerve activity. When used adjunctively, RecoveryRx has been found to reduce pain and the consumption of pain medication, including opioids. Our current published clinical data can be viewed at www.bielcorp.com

We’re working on a grant proposal for the National Vulvodynia Association and seek to partner with a medical professional who is excited about turning good clinical ideas into real-world evidence. This is an early-stage collaboration meaning no finalized protocol, no overwhelming paperwork (yet!), and no heavy upfront commitment. Just shared interest, clinical insight, and a desire to improve care for patients who truly need better options.

Please contact us at 301.874.4890 or email us at [email protected]

12/31/2025

As we welcome the New Year, we want to extend our sincere thanks and warmest wishes to our shareholders, vendors, and distribution partners. Your trust, collaboration, and continued support make everything we do possible. We’re grateful for the partnerships we’ve built and EXCITED FOR THE OPPORTUNITIES AHEAD. Wishing you and your families a Happy New Year filled with health, success, and shared growth. 🎉

12/25/2025

Merry Christmas! 🎄
To our loyal shareholders, trusted suppliers, and valued distribution partners—thank you for your continued support, partnership, and confidence throughout the year. We wish you and your families a joyful Christmas filled with peace, gratitude, and time well spent with loved ones.

11/26/2025

🍁 Happy Thanksgiving from BioElectronics Corporation! 🦃

As we gather for the holiday, we want to extend our heartfelt gratitude to everyone who makes our mission possible.
To our shareholders, thank you for believing in our vision.
To our vendors and partners, thank you for your collaboration and commitment.
And to our customers, thank you for trusting our technologies to help support healthier, more comfortable lives.

We are truly thankful for your continued support and look forward to an exciting year ahead.
Wishing you and your families a warm, joyful, and pain-free Thanksgiving holiday! 🍂 Our offices will reopen on Monday, December 1st.

11/11/2025

This Veterans Day, we pause to recognize and thank all who have served in the U.S. Armed Forces. Your commitment, discipline, and selfless service embody the very best of what it means to lead and protect. From all of us at BioElectronics Corpation — thank you for your service.

10/06/2025

Stanford University Study Finds PSWT Provides Sustained Pain Relief for One of the Most Common Forms of Hand Arthritis

We announce the completion and publication of a double-blind, randomized controlled clinical trial has shown that pulsed shortwave therapy (PSWT) provides sustained pain relief in adults with thumb carpometacarpal (CMC) joint osteoarthritis. The study was conducted at Stanford University. The study abstract can be viewed here https://journals.sagepub.com/doi/10.1177/15589447251371088

Thumb arthritis is one of the most common—and painful—forms of hand arthritis. It makes everyday tasks like turning doorknobs, buttoning a shirt, or opening a jar difficult. Current treatment options are limited, often involving splints, medications, or injections. This research suggests PSWT could be a safe, drug-free option that people can use at home—potentially changing how we treat this widespread condition for the estimated 4–7 million U.S. adults with symptomatic thumb CMC arthritis.

The study, involving 61 adults with clinically and/or radiographically diagnosed thumb CMC osteoarthritis, compared outcomes between participants using an active PSWT device and those using an identical-appearing sham device. Both groups wore their devices for approximately eight hours each night over a four-week period.

At four weeks, both groups reported meaningful reductions in pain, likely influenced by the splint-like stiffness of the devices and potential placebo effects. However, after device use was discontinued, thereby removing the splinting and placebo effects, only the PSWT group maintained its pain relief by week six. The difference in pain reduction between PSWT and sham groups at this point was highly statistically significant with a p value of .02.

Other measures—including maximum pain, hand function (PRWHE), and single-assessment scores (SANE)—improved in both groups during the treatment period.

Importantly, PSWT was found to be safe and well tolerated. Adverse events were infrequent and mild, most commonly minor skin irritation from the adhesive tape. No serious adverse events occurred.

Key findings:
• Both PSWT and sham groups experienced pain reduction at 4 weeks.
• At 6 weeks, only the PSWT group sustained improvement, resulting in a significant difference versus sham.
• Benefits were not solely explained by splinting effects, placebo response, or continued device use.
• PSWT was safe, with no serious adverse events reported.
“These findings suggest that PSWT may offer a true sustained analgesic benefit for thumb osteoarthritis,” said the study investigators.

About Pulsed Shortwave Therapy (PSWT)
PSWT is a non-invasive electromagnetic therapy designed to reduce pain and improve quality of life in patients with chronic musculoskeletal conditions. Unlike medications, PSWT has no systemic side effects and can be self-administered at home.

Background: Thumb carpometacarpal (CMC) osteoarthritis (OA) is a common source of hand pain with limited nonoperative treatment options. Pulsed electromagnetic ...

08/29/2025

Our office will be closed Monday, September 1, 2025 for the Labor Day Holiday. Wishing everyone a pain-free, happy and safe holiday weekend!